Georgiamune’s GIM-122 is being analysed in a Phase I/II trial for treating checkpoint refractory or resistant advanced solid tumours. Credit: Minerva Studio / Shutterstock.com.

Georgiamune and Verily have entered a strategic collaboration to advance new cancer treatments.

Verily’s molecular and real-world evidence offerings will be leveraged to develop Georgiamune’s drug candidates.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The solution will aid in detecting predictive and outcome biomarkers to develop the new therapeutics. 

Georgiamune and Verily will utilise clinical trial data and longitudinal real-world data sources for enhanced clinical development. 

Initially, the companies will deploy Verily’s Immune Profiler to carry out immune mapping of Georgiamune’s dual-functioning antibody, GIM-122. 

This antibody is currently being analysed for tolerability, safety and antitumour activity in a Phase I/II clinical trial for treating checkpoint refractory or resistant advanced solid tumours. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Immune Profiler will also be deployed to analyse GIM-122’s pharmacodynamic effect and immune response in patients. 

The collaboration will then be expanded into other cancer assets and treatment areas from Georgiamune, including autoimmune ailments. 

Georgiamune founder and CEO Dr Samir Khleif stated: “Verily’s expertise in immune profiling, real-world data and advanced analytics provide a comprehensive data profile to accelerate the development of our novel drug candidate. 

“This partnership will allow us to focus on identifying the patient population that could potentially benefit the most from our breakthrough discoveries.”